Genetic Predictors of QT Prolongation with Anti-arrhythmic Medication


About this study

The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being started on dofetilide. We will examine the predictiveness of a QT genotype score on QT prolongation in patients admitted for dofetilide initiation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients admitted to the hospital for initiation of dofetilide or sotalol on the basis of routine electrophysiologic care
  • All patients admitted to the hospital for dofetilide initiation will be eligible. 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Peter Noseworthy, M.D.

Open for enrollment

Contact information:

Jennifer Dugan


More information


Publications are currently not available

Mayo Clinic Footer